IP Verse

Arena Pharmaceuticals competitive analysis

Loading summary...

Latest patents of Arena Pharmaceuticals opposed by its competitors

Explore Arena Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3242666
Dec 25, 2024Methods Of Treating Conditions Related To The S1P1 Receptor4
EP3801459
Aug 7, 2024Methods Of Treating Conditions Related To The S1P1 Receptor4
EP3582814
May 1, 2024Compounds And Methods For Treatment Of Inflammatory Bowel Disease With Extra-Intestinal Manifestations2
EP3860590
Jun 7, 2023Methods For The Treatment Of Scleroderma3
EP3310760
Oct 19, 2022Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated Disorders2

Latest publications and patents of Arena Pharmaceuticals New

Explore the latest publications and patents granted to Arena Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Arena Pharmaceuticals

EP3242666
Dec 25, 2024Methods Of Treating Conditions Related To The S1P1 ReceptorGranted And Under Opposition
EP3801459
Aug 7, 2024Methods Of Treating Conditions Related To The S1P1 ReceptorRevoked
EP3582814
May 1, 2024Compounds And Methods For Treatment Of Inflammatory Bowel Disease With Extra-Intestinal ManifestationsRevoked
EP3860590
Jun 7, 2023Methods For The Treatment Of SclerodermaRevoked
EP3310760
Oct 19, 2022Crystalline L-Arginine Salt Of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[B]Indol-3-Yl)Acetic Acid(Compound1) For Use In Sipi Receptor-Associated DisordersGranted And Under Opposition
EP2364142
Jan 17, 2018Compositions Of A 5-Ht2A Serotonin Receptor Modulator Useful For The Treatment Of Disorders Related TheretoNo Opposition Filed Within Time Limit

Latest PTAB cases involving Arena Pharmaceuticals

Discover the latest PTAB cases involving Arena Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Arena Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ARENA PHARMACEUTICALS - 15 - -
MAIWALD136 - - -
SANDOZ1181619 -
TEVA PHARMACEUTICALS20916 - 12